Skip to main content
Article
P-30 Screening of Hybrid Arylidene Heterocyclic Boronic Acids as Potential Anticancer Agents in AU565 HER2/neu Breast Cancer Cell Line
Celebration of Research and Creative Scholarship
  • Jemma McLeish, Andrews University
  • Denise L. Smith, Andrews University
Presenter Status
Andrews University
Second Presenter Status
Instructor, Biology Department
Preferred Session
Poster Session
Start Date
4-11-2016 2:00 PM
End Date
4-11-2016 3:00 PM
Disciplines
Presentation Abstract
Cancers are a group of diseases that are characterized by uncontrollable cellular growth and can occur in any tissue or organ system. Breast cancer is one of the most frequently occurring cancers and the second leading cause of cancer-related deaths in women. With the increased incidence of cancers, a lot of research has been done to determine the cellular factors and pathways that are involved in their occurrence. This has resulted in developing treatment options that can be better targets and a rationale for synthesizing novel drugs that have the potential to produce anticancer effects. The hybrid arylidene heterocyclic boronic acids synthesized for this project were so done with the concept that combining two or more pharmacophores into a single unit may prove to be more effective than a single drug or multiple combined drug therapies. These hybrid drugs contain boronic acids and heterocycles such as rhodanine and its derivatives. Both of these components on their own have shown a range of biological activities such as anticancer, antiviral and antibacterial. Our research goal is focused on screening these hybrid compounds for anticancer activities in overexpressing HER2/neu positive breast cancer cell line AU565.
Citation Information
Jemma McLeish and Denise L. Smith. "P-30 Screening of Hybrid Arylidene Heterocyclic Boronic Acids as Potential Anticancer Agents in AU565 HER2/neu Breast Cancer Cell Line" (2016)
Available at: http://works.bepress.com/denise_smith/7/